Heart Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Heart transplantation is the therapy used in various heart diseases. Heart transplant replaces an injured or diseased heart with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted heart as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

The Heart Transplant Rejection pipeline drugs market research report provides comprehensive information on the therapeutics under development for Heart Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Heart Transplant Rejection and features dormant and discontinued projects.

Heart Transplant Rejection Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Heart Transplant Rejection pipeline drugs market are Janus Kinase, CD40 Ligand, Protein Kinase C Theta Type, T Cell Specific Surface Glycoprotein CD28, Tumor Necrosis Factor Receptor Superfamily Member 5, and V Type Proton ATPase 116 Kda Subunit A Isoform 3. Janus Kinase leads this segment of the Heart Transplant Rejection pipeline drugs market.

Heart Transplant Rejection Pipeline Drugs Market Analysis, by Targets

Heart Transplant Rejection Pipeline Drugs Market Analysis, by TargetsFor more Heart Transplant Rejection pipeline drugs market target insights, download a free report sample

Heart Transplant Rejection Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Heart Transplant Rejection pipeline drugs market are Janus Kinase Inhibitor, CD40 Ligand Inhibitor, Protein Kinase C Theta Type Inhibitor, T Cell Specific Surface Glycoprotein CD28 Antagonist, Tumor Necrosis Factor Receptor Superfamily Member 5 Antagonist, and V Type Proton ATPase 116 Kda Subunit A Isoform 3 Inhibitor. Janus Kinase Inhibitor leads the Heart Transplant Rejection pipeline drugs market in terms of MoA.

Heart Transplant Rejection Pipeline Drugs Market Analysis, by Mechanisms of Action

Heart Transplant Rejection Pipeline Drugs Market Analysis, by Mechanisms of ActionFor more mechanisms of action insights into the Heart Transplant Rejection pipeline drugs market, download a free report sample

Heart Transplant Rejection Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Heart Transplant Rejection pipeline drugs market are intravenous, parenteral, and subcutaneous. Intravenous leads the Heart Transplant Rejection pipeline drugs market in terms of RoA.

Heart Transplant Rejection Pipeline Drugs Market Analysis, by Routes of Administration

Heart Transplant Rejection Pipeline Drugs Market Analysis, by Routes of AdministrationFor more routes of administration insights into the Heart Transplant Rejection pipeline drugs market, download a free report sample

Heart Transplant Rejection Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Heart Transplant Rejection pipeline drugs market are monoclonal antibody, small molecule, cell therapy, and fusion protein. Monoclonal Antibody leads the Heart Transplant Rejection pipeline drugs market in terms of molecule types.

Heart Transplant Rejection Pipeline Drugs Market Analysis, by Molecule Types

Heart Transplant Rejection Pipeline Drugs Market Analysis, by Molecule TypesFor more molecule-type insights into the Heart Transplant Rejection pipeline drugs market, download a free report sample

Heart Transplant Rejection Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the Heart Transplant Rejection pipeline drugs market are Astellas Pharma Inc, Bristol-Myers Squibb Co, Kiniksa Pharmaceuticals Ltd, Nekonal Sarl, and Tonix Pharmaceuticals Holding Corp. Astellas Pharma Inc has the highest number of products under development.

Heart Transplant Rejection Pipeline Drugs Market Analysis, by Companies

Heart Transplant Rejection Pipeline Drugs Market Analysis, by CompaniesTo know more about the Heart Transplant Rejection pipeline drugs market companies, download a free report sample

Heart Transplant Rejection Pipeline Drugs Market Report Overview

Key Targets Janus Kinase, CD40 Ligand, Protein Kinase C Theta Type, T Cell Specific Surface Glycoprotein CD28, Tumor Necrosis Factor Receptor Superfamily Member 5, and V Type Proton ATPase 116 Kda Subunit A Isoform 3
Key Mechanisms of Action Janus Kinase Inhibitor, CD40 Ligand Inhibitor, Protein Kinase C Theta Type Inhibitor, T Cell Specific Surface Glycoprotein CD28 Antagonist, Tumor Necrosis Factor Receptor Superfamily Member 5 Antagonist, and V Type Proton ATPase 116 Kda Subunit A Isoform 3 Inhibitor
Key Routes of Administration Intravenous, Parenteral, and Subcutaneous
Key Molecule Types Monoclonal Antibody, Small Molecule, Cell Therapy, and Fusion Protein
Key Companies Astellas Pharma Inc, Bristol-Myers Squibb Co, Kiniksa Pharmaceuticals Ltd, Nekonal Sarl, and Tonix Pharmaceuticals Holding Corp

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Heart Transplant Rejection.
  • The pipeline guide reviews pipeline therapeutics for Heart Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Heart Transplant Rejection therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Heart Transplant Rejection therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Heart Transplant Rejection

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Heart Transplant Rejection.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the Heart Transplant Rejection pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Heart Transplant Rejection – Overview

Heart Transplant Rejection – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Heart Transplant Rejection – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Heart Transplant Rejection – Companies Involved in Therapeutics Development

Astellas Pharma Inc

Bristol-Myers Squibb Co

Kiniksa Pharmaceuticals Ltd

Nekonal Sarl

Tonix Pharmaceuticals Holding Corp

Heart Transplant Rejection – Drug Profiles

AS-2521780 – Drug Profile

Product Description

Mechanism Of Action

AS-2553627 – Drug Profile

Product Description

Mechanism Of Action

Autologous thyTreg – Drug Profile

Product Description

Mechanism Of Action

belatacept – Drug Profile

Product Description

Mechanism Of Action

KPL-404 – Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation – Drug Profile

Product Description

Mechanism Of Action

TNX-1500 – Drug Profile

Product Description

Mechanism Of Action

tofacitinib – Drug Profile

Product Description

Mechanism Of Action

Heart Transplant Rejection – Dormant Projects

Heart Transplant Rejection – Product Development Milestones

Featured News & Press Releases

May 31, 2022: Tonix Pharmaceuticals announces two oral presentations involving TNX-1500 (Fc-modified anti-CD40L mAb) on prevention of rejection in kidney and heart allograft transplantation at the 2022 American Transplant Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Heart Transplant Rejection, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Heart Transplant Rejection – Pipeline by Astellas Pharma Inc, 2022

Heart Transplant Rejection – Pipeline by Bristol-Myers Squibb Co, 2022

Heart Transplant Rejection – Pipeline by Kiniksa Pharmaceuticals Ltd, 2022

Heart Transplant Rejection – Pipeline by Nekonal Sarl, 2022

Heart Transplant Rejection – Pipeline by Tonix Pharmaceuticals Holding Corp, 2022

Heart Transplant Rejection – Dormant Projects, 2022

Figures

List of Figures

Number of Products under Development for Heart Transplant Rejection, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Heart Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Heart Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Heart Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.